Biotech News

Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update

Talphera Inc (TLPH)TalpheraEarnings

Briefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of December 31, 2026 Pivotal NEPHRO study currently exceeds 80% power for primary endpoint supporting a potential early close of enrollment Updated

Related news

Talphera Inc

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings. Its lead program addresses anticoagulation during continuous renal replacement therapy. Niyad Niyad is a regional citrate anticoagulant designed for use in the extracorporeal circuit during...

Recent company news

Stock data

Close
0.74 USD
Market cap
40.24M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States